CFI and dry age related macular degeneration: For dry AMD, there are currently two ongoing gene therapy trials, including GT005 (phase I) that induces ocular complement factor I (CFI) expression [20] and HMR59 (AAVCAGsCD59, phase I) that expresses C59 to prevent formation of the membrane attack complex (MAC) [21].